{"id":"long-dapt","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (major and minor)"},{"rate":null,"effect":"Gastrointestinal bleeding"},{"rate":null,"effect":"Intracranial hemorrhage"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DAPT (Dual Antiplatelet Therapy) combines two antiplatelet agents, typically aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor), to prevent stent thrombosis and recurrent ischemic events. Long DAPT refers to extended treatment duration beyond standard 12 months, aiming to further reduce atherothrombotic complications in high-risk patients, though at the cost of increased bleeding risk.","oneSentence":"Long DAPT extends dual antiplatelet therapy duration to reduce thrombotic cardiovascular events in patients with acute coronary syndrome or those undergoing percutaneous coronary intervention.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:23.164Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome post-percutaneous coronary intervention with stent placement"},{"name":"Prevention of stent thrombosis and recurrent ischemic events in high-risk patients"}]},"trialDetails":[{"nctId":"NCT07480629","phase":"","title":"The 10-Year Extended Follow-up of the DACAB Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Ruijin Hospital","startDate":"2026-03-15","conditions":"Coronary Artery Disease, CABG, Antiplatelet Therapy of Coronary Artery Bypass","enrollment":500},{"nctId":"NCT07379190","phase":"PHASE3","title":"HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)","status":"NOT_YET_RECRUITING","sponsor":"Weifang Medical University","startDate":"2026-02-01","conditions":"Stroke, Acute, Stroke, Ischemic, Cerebral Infarction","enrollment":458},{"nctId":"NCT04728516","phase":"PHASE4","title":"The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-04-12","conditions":"Acute Coronary Syndrome, Helicobacter Pylori Infection","enrollment":2600},{"nctId":"NCT03729401","phase":"PHASE4","title":"Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND","status":"SUSPENDED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2019-08-22","conditions":"Coronary Artery Disease, Myocardial Infarction","enrollment":390},{"nctId":"NCT05660811","phase":"PHASE4","title":"Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure in Dialyzed Patients","status":"RECRUITING","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2022-09-28","conditions":"Atrial Fibrillation","enrollment":80},{"nctId":"NCT04814212","phase":"NA","title":"Drug-Coated Balloon in Anticoagulated and Bleeding Risk Patients Undergoing PCI","status":"RECRUITING","sponsor":"North Karelia Central Hospital","startDate":"2022-09-01","conditions":"Coronary Artery Disease","enrollment":546},{"nctId":"NCT06084000","phase":"NA","title":"STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-10-15","conditions":"Drug-coated Balloon, Drug-eluting Stent, De Novo Stenosis","enrollment":2700},{"nctId":"NCT05996978","phase":"","title":"Intensive Drug Therapy for Ischemic Stroke Caused by Severe Intracranial Arterial Stenosis","status":"COMPLETED","sponsor":"Shanghai Yueyang Integrated Medicine Hospital","startDate":"2020-02-01","conditions":"Ischemic Stroke","enrollment":42},{"nctId":"NCT03445949","phase":"PHASE4","title":"Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure","status":"RECRUITING","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2018-01-23","conditions":"Atrial Fibrillation","enrollment":200},{"nctId":"NCT05671276","phase":"PHASE4","title":"Efficacy of Different Anti-Thrombotic Strategies on the Incidence of Silent Cerebral Embolism After Percutaneous Left Atrial Appendage Occlusion","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-02-01","conditions":"Atrial Fibrillation, Left Atrial Appendage Occlusion, Silent Cerebral Embolism","enrollment":150},{"nctId":"NCT05620615","phase":"","title":"Intensive Drug Therapy for Ischemic Stroke","status":"UNKNOWN","sponsor":"Shanghai Yueyang Integrated Medicine Hospital","startDate":"2018-07-01","conditions":"Ischemic Stroke","enrollment":42},{"nctId":"NCT04734028","phase":"","title":"PTRG-DES Consortium","status":"COMPLETED","sponsor":"Gyeongsang National University Hospital","startDate":"2003-07-09","conditions":"Coronary Artery Disease, Clopidogrel, Poor Metabolism of, Platelet Dysfunction","enrollment":13160},{"nctId":"NCT01925794","phase":"NA","title":"COBRA PZF™ Coronary Stent for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term DAPT","status":"COMPLETED","sponsor":"CeloNova BioSciences, Inc.","startDate":"2013-08-21","conditions":"Coronary Artery Disease","enrollment":296},{"nctId":"NCT03877848","phase":"","title":"EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study","status":"COMPLETED","sponsor":"Medinol Ltd.","startDate":"2019-05-06","conditions":"Coronary Stenosis","enrollment":319},{"nctId":"NCT04850417","phase":"PHASE4","title":"Randomized Study of Beta-Blockers and Antiplatelets in Patients With Spontaneous Coronary Artery Dissection","status":"NOT_YET_RECRUITING","sponsor":"Spanish Society of Cardiology","startDate":"2021-04-30","conditions":"Spontaneous Coronary Artery Dissection","enrollment":600},{"nctId":"NCT02224235","phase":"NA","title":"COBRA SHIELD OCT Study","status":"TERMINATED","sponsor":"CeloNova BioSciences, Inc.","startDate":"2014-06","conditions":"Stable Angina","enrollment":8},{"nctId":"NCT02513810","phase":"NA","title":"A Randomized Controlled Comparison Between One Versus More Than Six Months of Dual Antiplatelet Therapy After Biolimus A9-eluting Stent Implantation","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2015-12-02","conditions":"Coronary Artery Disease","enrollment":3020},{"nctId":"NCT03224923","phase":"PHASE4","title":"A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)","status":"TERMINATED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2017-08-18","conditions":"Stable Coronary Syndrome, Percutaneous Coronary Intervention, Antiplatelet Therapy","enrollment":5},{"nctId":"NCT02798913","phase":"PHASE3","title":"Effects of Prolonged DAPT After Lower Extremity Percutaneous Transluminal Angioplasty (PTA) in Patients With LE-PAD","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2016-01","conditions":"Peripheral Artery Disease","enrollment":300},{"nctId":"NCT02118870","phase":"PHASE4","title":"Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent","status":"COMPLETED","sponsor":"Diagram B.V.","startDate":"2014-06-10","conditions":"Acute Coronary Syndrome","enrollment":1500},{"nctId":"NCT02494284","phase":"PHASE4","title":"Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation","status":"TERMINATED","sponsor":"CHEOL WHAN LEE, M.D., Ph.D","startDate":"2015-12-22","conditions":"Coronary Artery Disease","enrollment":364},{"nctId":"NCT01514227","phase":"PHASE4","title":"Nobori Dual Antiplatelet Therapy as Appropriate Duration","status":"COMPLETED","sponsor":"Associations for Establishment of Evidence in Interventions","startDate":"2011-12","conditions":"Coronary Artery Disease","enrollment":3773},{"nctId":"NCT01192724","phase":"PHASE4","title":"Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-03","conditions":"Coronary Artery Disease","enrollment":630},{"nctId":"NCT02806102","phase":"","title":"CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Acute Myocardial Infarction II (COREA-AMI II)","status":"UNKNOWN","sponsor":"Seoul St. Mary's Hospital","startDate":"2004-01","conditions":"Acute Myocardial Infarction, Percutaneous Coronary Intervention, Major Adverse Cardiovascular Events","enrollment":13000},{"nctId":"NCT01325935","phase":"PHASE4","title":"Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients","status":"COMPLETED","sponsor":"Associations for Establishment of Evidence in Interventions","startDate":"2011-04","conditions":"Coronary Artery Disease","enrollment":1187},{"nctId":"NCT01385319","phase":"PHASE3","title":"Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study","status":"UNKNOWN","sponsor":"Marco Valgimigli","startDate":"2011-06","conditions":"Coronary Artery Disease","enrollment":1606}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["12 months ASA + Clopidogrel"],"phase":"phase_3","status":"active","brandName":"Long DAPT","genericName":"Long DAPT","companyName":"Federico II University","companyId":"federico-ii-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Long DAPT extends dual antiplatelet therapy duration to reduce thrombotic cardiovascular events in patients with acute coronary syndrome or those undergoing percutaneous coronary intervention. Used for Acute coronary syndrome post-percutaneous coronary intervention with stent placement, Prevention of stent thrombosis and recurrent ischemic events in high-risk patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}